Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Twynsta 10-80 Mg Tabs 30 By Boehringer Ingelheim

Image 0 of Twynsta 10-80 Mg Tabs 30 By Boehringer IngelheimImage 1 of Twynsta 10-80 Mg Tabs 30 By Boehringer Ingelheim

Twynsta 10-80 Mg Tabs 30 By Boehringer Ingelheim

Call for Price

Twynsta 10-80 Mg Tabs 30 By Boehringer Ingelheim. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4261442/RXA321334
Generic Name: TELMISARTAN/AMLODIPINE
Description: TWYNSTA TB 80-10MG 30 BPK
CIN: 4261442
NDC:00597-0127-37
UPC: 305970-127376
Contract:
Contract Alias:
Strength: 80-10MG
Form: TABLETS
Size:
1X30 EA

Have a question?

  Call for Price

Product Description.:

Logo and A4
tablet , blue white , oval oblong
BiconvexDebossedmultilayered tabletWhite to off-white

TWYNSTA is a fixed dose combination of telmisartan and amlodipine. TWYNSTA tablets contain the besylate salt of amlodipine, a dihydropyridine calcium-channel blocker (CCB).TWYNSTA tablets are formulated in four strengths for oral administration with a combination of amlodipine besylate, equivalent to 5 mg or 10 mg or amlodipine free-base, with 40 mg, or 80 mg or telmisartan provided in the following four combinations: 40/5 mg, 40/10 mg, 80/5 mg, and 80/10 mg.

TWYNSTA tablets also contain the following inactive ingredients: sodium hydroxide, povidone, meglumine, sorbitol, magnesium stearate, microcrystalline cellulose, pregelatinized starch, corn starch, colloidal silicon dioxide, ferric oxide black, ferric oxide yellow and FD&C blue #1.

TWYNSTA tablets are hygroscopic and require protection from moisture. TWYNSTA tablets require protection from light.

INDICATIONS

TWYNSTA (telmisartan/amlodipine) tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents.

TWYNSTA tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

Base the choice of TWYNSTA tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of TWYNSTA tablets.

Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use TWYNSTA tablets as initial therapy. Individual blood pressure goals may vary based upon the patient's risk.

SIDE EFFECTS
Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
TWYNSTA Tablets

The concomitant use of telmisartan and amlodipine has been evaluated for safety in more than 3700 patients with hypertension approximately 1900 of these patients were exposed for at least 6 months and over 160 of these patients were exposed for at least one year. Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.

In the placebo-controlled factorial design study, the population treated with a telmisartan and amlodipine combination had a mean age of 53 years and included approximately 50% males, 79% were Caucasian, 17% Blacks, and 4% Asians. Patients received doses ranging from 20/2.5 mg to 80/10 mg orally, once daily.